J-Y Douillard
Overview
Explore the profile of J-Y Douillard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
5350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Latino N, Galotti M, Cherny N, de Vries E, Douillard J, Kaidarova D, et al.
ESMO Open
. 2022 Mar;
7(1):100362.
PMID: 35246325
Background: In Kazakhstan, cancer is the second leading cause of death with a major public health and economic burden. In the last decade, cancer care and cancer medicine costs have...
2.
Mandelker D, Donoghue M, Talukdar S, Bandlamudi C, Srinivasan P, Vivek M, et al.
Ann Oncol
. 2021 Jun;
32(8):1069-1071.
PMID: 34090768
No abstract available.
3.
Ferrari A, Stark D, Peccatori F, Fern L, Laurence V, Gaspar N, et al.
ESMO Open
. 2021 Apr;
6(2):100096.
PMID: 33926710
It is well recognised that adolescents and young adults (AYA) with cancer have inequitable access to oncology services that provide expert cancer care and consider their unique needs. Subsequently, survival...
4.
Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec J, Lacroix L, et al.
Ann Oncol
. 2021 Jan;
32(3):337-350.
PMID: 33455880
Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities have been tested in RET-altered tumours with variable...
5.
Mosele F, Remon J, Mateo J, Westphalen C, Barlesi F, Lolkema M, et al.
Ann Oncol
. 2020 Aug;
31(11):1491-1505.
PMID: 32853681
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no...
6.
Yoshino T, Pentheroudakis G, Mishima S, Overman M, Yeh K, Baba E, et al.
Ann Oncol
. 2020 Apr;
31(7):861-872.
PMID: 32272210
A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese Society of Medical Oncology (JSMO),...
7.
Park Y, Senkus-Konefka E, Im S, Pentheroudakis G, Saji S, Gupta S, et al.
Ann Oncol
. 2020 Feb;
31(4):451-469.
PMID: 32081575
In view of the planned new edition of the most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of...
8.
Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, et al.
Ann Oncol
. 2020 Feb;
31(3):334-351.
PMID: 32067677
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and...
9.
Park K, Vansteenkiste J, Lee K, Pentheroudakis G, Zhou C, Prabhash K, et al.
Ann Oncol
. 2020 Jan;
31(2):191-201.
PMID: 31959336
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced non-small-cell lung cancer (NSCLC) was...
10.
Marchio C, Scaltriti M, Ladanyi M, Iafrate A, Bibeau F, Dietel M, et al.
Ann Oncol
. 2019 Jul;
30(9):1417-1427.
PMID: 31268127
Background: NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most frequent mechanism of oncogenic activation of these receptor tyrosine...